Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data esta ...

The Zacks analyst believes that the planned launch of an in-house ad tech platform next year signals the ... Kisqali, Pluvicto Drive Novartis (NVS) Amid Competition Per the Zacks analyst, drugs like ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

We expect our cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement ...

The reacquisition of the full global commercial rights to ociperlimab and TEVIMBRA in the third quarter of 2023 resulted in ...

Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across ...